Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients
NCT ID: NCT05642793
Last Updated: 2022-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
80 participants
INTERVENTIONAL
2022-04-01
2024-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1 (proactive use of conbercept after vitrectomy)
proactive use of conbercept after vitrectomy
proactive Anti-VEGF (conbercept) use
preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
group 2 (passive use of conbercept after vitrectomy)
passive use of conbercept after vitrectomy
passive Anti-VEGF (conbercept) use
No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
proactive Anti-VEGF (conbercept) use
preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
passive Anti-VEGF (conbercept) use
No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients who had received intravitreal injection or systemic use of all types of steroid in the recent one month before vitrectomy
* patients who had received complete PRP before vitrectomy
* patients who are pregnant
19 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chen Huijin
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Huijin Chen, Dr.
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Huijin Chen, Dr.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PDR vitrectomy1
Identifier Type: -
Identifier Source: org_study_id